| 李璐璐,贾红燕,董 亮,毕恺欣,李坤艳.血清ANXA2、ANXA6、ANXA7与乳腺癌患者聚乙二醇多柔比星脂质体相关新辅助化疗方案治疗疗效的关系研究[J].,2024,(10):1996-2000 |
| 血清ANXA2、ANXA6、ANXA7与乳腺癌患者聚乙二醇多柔比星脂质体相关新辅助化疗方案治疗疗效的关系研究 |
| Relationship between Serum ANXA2, ANXA6, ANXA7 and the Efficacy of Polyethylene Glycol Doxorubicin Liposome-Related Neoadjuvant Chemotherapy in Breast Cancer Patients |
| 投稿时间：2023-10-23 修订日期：2023-11-18 |
| DOI：10.13241/j.cnki.pmb.2024.10.040 |
| 中文关键词: 乳腺癌 新辅助化疗 乙二醇多柔比星脂质体 ANXA2 ANXA6 ANXA7 预测价值 |
| 英文关键词: Breast cancer Neoadjuvant chemotherapy Polyethylene glycol doxorubicin liposome ANXA2 ANXA6 ANXA7 Predictive value |
| 基金项目:山西省回国留学人员科研资助项目（2021-157） |
|
| 摘要点击次数: 255 |
| 全文下载次数: 195 |
| 中文摘要: |
| 摘要 目的：探讨血清膜联蛋白A2（ANXA2）、膜联蛋白A6（ANXA6）、膜联蛋白A7（ANXA7）与乳腺癌患者聚乙二醇多柔比星脂质体（PLD）相关新辅助化疗方案治疗疗效的关系。方法：选择2019年11月至2022年12月于山西医科大学第一医院95例行PLD相关新辅助化疗的乳腺癌患者。新辅助化疗前检测所有乳腺癌患者的血清ANXA2、ANXA6、ANXA7水平。单因素和多因素Logistic回归分析影响乳腺癌患者PLD相关新辅助化疗疗效的因素。受试者工作特征（ROC）曲线分析血清ANXA2、ANXA6、ANXA7预测乳腺癌患者PLD相关新辅助化疗疗效的价值。结果：无效组新辅助化疗前血清ANXA2、ANXA6、ANXA7水平均高于有效组（P＜0.05）。TNM分期IIIA期、ER阳性、高水平ANXA2、高水平ANXA6、高水平ANXA7是乳腺癌PLD相关新辅助化疗无效的危险因素（P＜0.05）。血清ANXA2、ANXA6、ANXA7单独检测预测乳腺癌PLD相关新辅助化疗无效的曲线下面积分别为0.783、0.774、0.821，三指标联合检测预测的曲线下面积为0.923，高于各指标单独预测效能。结论：高ANXA2、ANXA6、ANXA7水平及TNM分期ⅢA期、ER阳性均是乳腺癌患者PLD相关新辅助化疗无效的危险因素，联合检测血清ANXA2、ANXA6、ANXA7水平可提高对乳腺癌患者PLD相关新辅助化疗疗效的预测效能。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum annexin A2 (ANXA2), annexin A6 (ANXA6), annexin A7 (ANXA7) and the efficacy of polyethylene glycol doxorubicin liposome (PLD) -related neoadjuvant chemotherapy in breast cancer patients. Methods: 95 breast cancer patients who were underwent PLD-related neoadjuvant chemotherapy in the First Hospital of Shanxi Medical University from November 2019 to December 2022 were selected. The levels of serum ANXA2, ANXA6 and ANXA7 in all breast cancer patients were detected before neoadjuvant chemotherapy. The factors affecting the efficacy of PLD-related neoadjuvant chemotherapy in breast cancer patients were analyzed by univariate and multivariate Logistic regression analysis. The value of serum ANXA2, ANXA6 and ANXA7 in predicting the efficacy of PLD-related neoadjuvant chemotherapy in breast cancer patients were analyzed by receiver operating characteristic (ROC) curve. Results: The levels of serum ANXA2, ANXA6 and ANXA7 before neoadjuvant chemotherapy in ineffective group were higher than those in effective group (P<0.05). TNM stage IIIA, ER positive, high level of ANXA2, high level of ANXA6 and high level of ANXA7 were risk factors for the failure of PLD-related neoadjuvant chemotherapy in breast cancer (P<0.05). The area under the curve of serum ANXA2, ANXA6 and ANXA7 alone in predicting the failure of PLD-related neoadjuvant chemotherapy for breast cancer was 0.783, 0.774 and 0.821, respectively, the area under the curve predicted by the combined detection of the three indicators was 0.923, which was higher than that of each indicator alone. Conclusion: The high levels of ANXA2, ANXA6 and ANXA7, TNM stage IIIA and ER positive are all risk factors for the failure of PLD-related neoadjuvant chemotherapy in breast cancer patients. Combined detection of serum ANXA2, ANXA6 and ANXA7 levels can improve the predictive efficacy of PLD-related neoadjuvant chemotherapy in breast cancer patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
